Verily, the precision health subsidiary of Alphabet, and Samsung Electronics have announced a comprehensive strategic collaboration aimed at revolutionizing the landscape of clinical research by integrating consumer wearable data into large-scale medical studies. The announcement, made during the HIMSS (Healthcare Information and Management Systems Society) global conference in Las Vegas, signals a significant shift in how pharmaceutical companies, academic researchers, and government agencies collect and utilize real-world health data. By bridging the gap between consumer-grade hardware and clinical-grade data requirements, the partnership seeks to streamline the often cumbersome process of monitoring study participants, potentially accelerating the development of new therapies and medical interventions.
The core of the collaboration involves the deep integration of Samsung Galaxy Watch user data into Verily’s precision health platform, known as Verily Pre. This integration allows researchers to move beyond traditional, intermittent clinical visits and instead capture a continuous, longitudinal view of a patient’s health. As the healthcare industry increasingly moves toward decentralized clinical trials (DCTs), the ability to monitor participants remotely through devices they already wear daily is seen as a critical component in reducing the burden on patients and improving the quality of data collected.
Bridging the Gap Between Consumer Tech and Clinical Rigor
For years, a significant barrier to using consumer wearables in formal clinical trials has been the perceived lack of data "rigor" required by regulatory bodies like the U.S. Food and Drug Administration (FDA). However, the landscape is shifting. Myoung Cha, Verily’s Chief Product Officer and the former head of health strategic initiatives at Apple, emphasized that consumer wearables have matured into "real, bonafide research-grade instruments." This evolution is driven by advancements in sensor technology, including the sophisticated BioActive Sensor found in Samsung’s latest Galaxy Watch models, which can provide highly accurate readings for heart rate, blood pressure, and even body composition.
The challenge, according to Cha, is not just the hardware but the infrastructure required to manage the massive influx of data. Verily Pre acts as the necessary intermediary—a platform capable of ingesting, harmonizing, and curating data to ensure it complies with strict research protocols. By the time this data reaches a pharmaceutical company’s research set, it is already "cleaned" and organized, making it ready for immediate analysis and the generation of insights. This "bundled solution" is designed specifically to lower the friction for pharmaceutical companies that may have been hesitant to adopt wearable technology due to technical or regulatory complexities.
Technical Architecture: From Raw Signals to Digital Biomarkers
One of the most significant aspects of this partnership is the level of data access granted to researchers. Unlike standard consumer apps that provide summary statistics—such as total steps taken or average heart rate—this collaboration provides access to raw device signals. Researchers will be able to analyze photoplethysmography (PPG) data and motion data from the Galaxy watches’ high-precision accelerometers and gyroscopes.
This granular access is essential for the development of "digital biomarkers." A digital biomarker is a quantifiable physiological or behavioral data point collected by digital devices that can be used to predict health outcomes or detect the onset of disease. For example, subtle changes in gait or tremors captured by a watch’s motion sensors could serve as an early warning sign for neurological conditions. Verily has already demonstrated the potential of this approach through its work with the Michael J. Fox Foundation, where wearable data was used to generate high-dimensional molecular datasets for Parkinson’s disease research.
By analyzing raw data points, developers can create algorithms that detect health fluctuations far more subtle than what a human clinician might observe during a biannual check-up. This continuous stream of "real-world data" (RWD) provides a more holistic view of how a drug or treatment affects a patient’s daily life, rather than just their performance in a clinical setting.
The Economic and Operational Impact on Clinical Trials
The pharmaceutical industry is currently facing a dual crisis of rising costs and low efficiency in drug development. On average, it takes over a decade and more than $2.6 billion to bring a new drug to market, with clinical trials accounting for a massive portion of that expenditure. Traditional trials are often plagued by high dropout rates, slow recruitment, and a lack of diversity among participants.
The Verily-Samsung partnership addresses these pain points by facilitating decentralized and hybrid trial models. When participants can contribute data from the comfort of their homes using a Samsung Galaxy Watch, the geographic barriers to participation are significantly lowered. This allows for a more diverse and representative study population, which is crucial for understanding how treatments affect different demographics. Furthermore, remote monitoring reduces the need for frequent travel to clinical sites, which is one of the primary reasons participants drop out of long-term studies.
From an operational standpoint, the partners are offering an end-to-end system. This includes the deployment of the hardware to participants, the remote collection of data through the Verily Pre platform, and the final analysis of results. By consolidating these steps into a single ecosystem, the collaboration aims to significantly reduce the administrative and technical overhead that currently hampers the adoption of digital health tools in research.
Contextualizing the HIMSS Announcement
The timing of the announcement at HIMSS is noteworthy. The conference is the premier event for healthcare information technology, attracting thousands of professionals focused on the digital transformation of medicine. This year, the overarching themes have centered on the use of artificial intelligence (AI) in healthcare and the integration of diverse data sources to provide a more personalized approach to medicine.
The Verily-Samsung deal fits perfectly within this narrative of "precision health." Precision health aims to deliver the right intervention to the right person at the right time by considering individual variability in genes, environment, and lifestyle. Wearable data provides the "lifestyle" and "environment" components of that equation, which have historically been the most difficult to track accurately.
Industry Reactions and Broader Implications
While specific pharmaceutical partners were not named in the initial announcement, the industry has shown a growing appetite for such collaborations. Competitors like Apple and Fitbit (owned by Google, Verily’s sister company) have also been making inroads into the clinical space. However, the Samsung-Verily alliance is unique in its focus on providing a "pharma-ready" platform that prioritizes raw data access and regulatory compliance over simple consumer engagement.
Analysts suggest that this partnership could trigger a "data arms race" in the wearable market, where the value of a device is measured not just by its consumer features, but by its utility in the multi-billion dollar clinical research industry. Furthermore, the involvement of government agencies—as mentioned in the announcement—suggests that public health initiatives could also benefit from this infrastructure, potentially using wearable data to monitor population health or track the spread of chronic diseases.
Future Outlook: The Road to Widespread Adoption
Despite the promise of the collaboration, several hurdles remain. Data privacy and security continue to be paramount concerns for both participants and regulators. Verily and Samsung must ensure that the sensitive health data collected is handled with the highest levels of encryption and in compliance with global standards like HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation).
Additionally, there is the challenge of standardization. For wearable data to be truly useful across the industry, there must be common formats and benchmarks for what constitutes "research-grade" data. The Verily Pre platform’s goal of "harmonizing" data is a step in this direction, but industry-wide consensus will be required for these digital biomarkers to be fully accepted as primary endpoints in clinical trials.
Looking ahead, the partnership plans to expand the range of health conditions being studied. Beyond Parkinson’s disease, there is significant potential for using wearable data to monitor cardiovascular health, sleep disorders, and metabolic conditions like diabetes. As algorithms become more sophisticated and sensors become more precise, the line between a consumer smartwatch and a medical diagnostic tool will continue to blur.
The collaboration between Verily and Samsung represents a maturing of the digital health industry. It moves the conversation away from "can we collect this data?" to "how can we use this data to save lives?" By providing the infrastructure and the hardware necessary to conduct high-quality, remote clinical research, the two companies are setting a new standard for how the medical community interacts with the technology on our wrists. As this end-to-end system begins to be deployed in upcoming trials, the insights generated could lead to a new era of faster, cheaper, and more effective medical research.
